Identification of a functional SNP in the 3′UTR of CXCR2 that is associated with reduced risk of lung cancer

Cancer Research

Volumn 75, Issue 3, 2015, Pages 566-575

  Ryan, Bríd M ^a   Robles, Ana I ^a   McClary, Andrew C ^a,b   Haznadar, Majda ^a   Bowman, Elise D ^a   Pine, Sharon R ^c   Brown, Derek ^a   Khan, Mohammed ^a   Shiraishi, Kouya ^d   Kohno, Takashi ^d   Okayama, Hirokazu ^a,d   Modali, Ramakrishna ^e   Yokota, Jun ^d   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e BioServe Biotechnologies Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; MICRORNA; MICRORNA 516A 3P; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; LIGAND;

3' UNTRANSLATED REGION; AGED; ALLELE; ARTICLE; BINDING SITE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CXCR2 GENE; DOWN REGULATION; EUROPEAN AMERICAN; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISTOLOGY; HUMAN; JAPANESE (PEOPLE); LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; RNA BINDING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; JAPAN; LUNG TUMOR; METABOLISM; MIDDLE AGED; RISK FACTOR;

3' UNTRANSLATED REGIONS; AGED; ALLELES; BINDING SITES; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GENOTYPE; HUMANS; INTERLEUKIN-8; JAPAN; LIGANDS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-8B; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84961288513     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2101     Document Type: Article

References (50)

1. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
2. De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 2006;312:1215-7.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
4. Rajewsky N. microRNA target predictions in animals. Nat Genet 2006;38: S8-13.
5. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
6. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10: 389-402.
7. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 2012;13:271-82.
8. Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A 2007;104:3300-5.
9. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006;38:1452-6.
10. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005;310:317-20.
11. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, et al. A mutation creating a potential illegitimate microRNA target site in themyostatin gene affects muscularity in sheep. Nat Genet 2006;38:813-8.
12. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. HumanmicroRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: amechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007;81:405-13.
13. Hanin G, Shenhar-Tsarfaty S, Yayon N, Hoe YY, Bennett ER, Sklan EH, et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet 2014;23:4569-80.
14. Lv K, Guo Y, Zhang Y, Wang K, Jia Y, Sun S. Allele-specific targeting of hsa-miR- 657 to human IGF2R creates a potential mechanism underlying the association of ACAA-insertion/deletion polymorphism with type 2 diabetes. Biochem Biophys Res Commun 2008;374:101-5.
15. Richardson K, Louie-Gao Q, Arnett DK, Parnell LD, Lai CQ, Davalos A, et al. The PLIN4 variant rs8887 modulates obesity related phenotypes in humans through creation of a novel miR-522 seed site. PLoS ONE 2011;6:e17944.
16. Kulkarni S, Qi Y, O'HUigin C, Pereyra F, Ramsuran V, McLaren P, et al. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci U S A 2013;110:20705-10.
17. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29:579-84.
18. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68: 8535-40.
19. Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, et al. MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res 2013;73: 1867-75.
20. Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun 2013;430: 529-34.
21. Xiong F, Wu C, Chang J, Yu D, Xu B, Yuan P, et al. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 2011;71:5175-81.
22. Zheng YL, Loffredo CA, Yu Z, Jones RT, Krasna MJ, Alberg AJ, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
23. Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, Goto K, et al. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 2010;31:834-41.
24. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D. Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 2010;38:D640-51.
25. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, Williams RW, et al. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007;35:D51-4.
26. Kruger J, Rehmsmeier M. RNAhybrid: microRNAtarget prediction easy, fast and flexible. Nucleic Acids Res 2006;34:W451-4.
27. VanderWeele TJ. On the distinction between interaction and effect modification. Epidemiology 2009;20:863-71.
28. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary note. Am J Epidemiol 2003;158:251-8.
29. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol 2011;26:433-8.
30. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, Creactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103: 1112-22.
31. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72:100-11.
32. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
33. Thomas LF, Saetrom P. Circular RNAs are depleted of polymorphisms at microRNA binding sites. Bioinformatics 2014;30:2243-6.
34. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37-49.
35. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in neversmokers. Proc Natl Acad Sci U S A 2009;106:12085-90.
36. Lianoglou S, Garg V, Yang JL, Leslie CS, Mayr C. Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. Genes Dev 2013;27:2380-96.
37. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67:6854-62.
38. Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005;14:2487-93.
39. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
40. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012;122:3127-44.
41. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
42. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000;165: 5269-77.
43. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2013;73:571-82.
44. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133:1006-18.
45. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40.
46. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.
47. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10:51-7.
48. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004;91:355-8.
49. Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer? Cancer Res 2009;69:2167-70.
50. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009;137:647-58.